Ph I/II Ipilimumab Vemurafenib Combo
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | November 2011 |
| End Date: | August 2015 |
| Contact: | For participation information at a USA site use a phone number below. For site information outside the USA please email: |
| Email: | Clinical.Trials@bms.com |
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form
of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib,
and the Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) inhibitor mAb Ipilimumab will be safe and
feasible and will show preliminary evidence of anti-tumor efficacy and survival in
comparison to historical results following treatment with either agent alone.
Inclusion Criteria:
- Metastatic melanoma with activating V600 BRAF mutation
- Measurable Tumor
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
Exclusion Criteria:
- Autoimmune disease
- Active Brain Metastasis (must be stable after radiation for at least one month)
- Prior therapy with immune stimulating agents
We found this trial at
3
sites
Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private...
Click here to add this to my saved trials
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials